Sarepta Therapeutics investor relations material

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The Company's product candidates include eteplirsen (EXONDYS 51), an exon-skipping agent that is used in treating Duchenne muscular dystrophy (DMD), drisapersen (MIRAGE) for the treatment of moderate to severe hypoactive sexual desire disorder (HSDD) associated with female hypoactive sexual desire disorder (FHSDD); and drisapersen for the treatment of DMD. The Company has collaboration agreements with with several other biopharmaceutical companies.